February 16, 2022 -- Evotec has made an equity investment in IMIDomics. In conjunction with the investment, an Evotec representative will join IMIDomics' board of directors.
Immune-mediated inflammatory diseases (IMIDs) affect nearly 1 in 10 people. The complexity of these diseases means getting a diagnosis can be a long-term struggle for patients, and then finding a treatment that works can be a frustrating, time-consuming, trial-and-error process, the company said in a press release.
The investment will advance IMIDomics' Precision Discovery Engine. The engine enables an understanding of how IMIDs work within patients via a combination of clinical and computational expertise with patient biological samples from the Vall d'Hebron Hospital IMID Biobank, which is collected from more than 17,000 IMID patients and control subjects from across 150 health centers, IMIDomics said. Ultimately, the engine's purpose is to discover medicines that will materially impact IMID patients' lives.
No financial details were disclosed.
IMIDomics is a global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with IMIDs.
Copyright © 2022 scienceboard.net